In this issue of JAMA Otolaryngology–Head & Neck Surgery, Wolf et al describe very high survival rates in an unselected cohort of 247 patients with advanced laryngeal cancer. These patients were treated with a program of individualized bioselection. All of us invested in the care of patients with advanced laryngeal cancer must breathe a deep sigh of relief. Only 10 years ago, Hoffman et al, in a landmark review of the national cancer database, evaluated the outcome of 158 426 patients with laryngeal cancer. Between the years of 1985 and 2001, the survival rate had gone down. So what has changed?
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2klVzzx
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
Article content meets expectations Minimal relevance to assigned subject matter. Article content fails to meet all requirements Not Rubric f...
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου